@article{TLCR21690,
author = {Yi-Long Wu and Chang-Li Wang and Mei-Lin Liao and Zhong-Zhen Guan and Chen-Yan Gao and Shun Lu and Ming- Fang Zhao and Jie Wang and Xiao-Qing Liu and Jin-Ji Yang and Jun Liang and Wei-Min Mao and Bao-Hui Han and Xu- Chao Zhang and Yong Song and Ji-Feng Feng and Sheng-Lin Ma and Gang Wu and Cai-Cun Zhou and Ke-Neng Chen and Ying Cheng and Yong He and Chun Chen and Qun Wang and Ji-Zhen Lin and Bo Zhu and Yun-Peng Liu and Yi Hu and Gui-Bin Qiao and Qing Zhou and Qi-Bin Song and Nan Wu and Lin Wu and Cheng Huang and Xiao-Long Fu and Jian-Ping Xiong and Jie Hu and Cheng-Ping Hu and Jian-Hua Chang and Qiong Zhao and Jun Zhao and Peng- Hui Zhou and Zhi-Yong Ma and Yuan Chen and He-Long Zhang and Fan Yang and Jian-Jun Wang and Yue-Yin Pan and Xue-Ning Yang and Yun Fan and Zhe Liu and Wen Fan and Nong Yang and Yan-Fang Guan and Hao Sun and Wen-Zhao Zhong},
title = {A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel},
journal = {Translational Lung Cancer Research},
volume = {7},
number = {3},
year = {2018},
keywords = {},
abstract = {The notable clinical success of cancer immunotherapy using checkpoint blockade suggests that it is likely to form the foundation of curative therapy for many malignancies. However, checkpoint blockades do not achieve sustained clinical response in most patients and thus amounts of problems needed to be figured out. Regarding these challenges, the 2017 Chinese Lung Cancer Summit expert panel organized a forum on the 14th Chinese Lung Cancer Summit to formally discuss these controversies. Five consensuses finally were reached to guide the application of checkpoint blockades.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/21690}
}